Opto Circuits gets USFDA clearance to market new AED

Medical devices firm Opto Circuits India today said its US arm Cardiac Science has received US health regulator's clearance to market its new automated external defibrillator (AED) in the American market.
Cardiac Science's 'Powerheart G5 AED with CRPD' has received 510(k) market clearance from the United States Food and Drug Administration (USFDA), allowing it to begin selling the product along with Powerheart G3 and G5 product line, Opto Circuits said in a statement.
Commenting on the development, Opto Circuits (India) Ltd Chairman and Managing Director Vinod Ramnani said: "This... Is a testament to the commitment shown by our employees who have spent many years of developing, testing and refining the Powerheart G5 so that seasoned and first-time rescuers will have the most reliable, easy-to-use AED in US marketplace."

The Powerheart family of AEDs is designed to enable rescuers to swiftly provide effective, life-saving therapy to aid a person who has suffered sudden cardiac arrest, a condition in which the heart suddenly stops beating due to ill regularities in its electrical system, Opto Circuits India said.
Shares of Opto Circuits India today closed at Rs 21.15 per scrip on BSE, up 7.36 per cent from previous close.